Lower risk of new atrial fibrillation in patients treated with semaglutide: Updated review and analysis of clinical trials

Semaglutide treatment is associated with a 17% reduction in new-onset atrial fibrillation incidence in randomized clinical trials.

• The analysis included 26 randomized clinical trials with 48,583 participants, of whom 25,879 received semaglutide.
• New-onset atrial fibrillation was reported in 541 participants across the trials.
• The oral formulation of semaglutide resulted in a 52% reduction in new-onset atrial fibrillation incidence.
• Studies with active comparators showed a 59% reduced risk of new-onset atrial fibrillation.
• In trials without Sodium-Glucose Co-Transporter 2 inhibitors, there was a 21% reduction in new-onset atrial fibrillation.
• Baseline characteristics, including BMI and HbA1c, did not influence the effect of semaglutide on atrial fibrillation incidence.

Simplified